Preferred Label : pyrrolidines;
MeSH definition : Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH.;
MeSH synonym : Tetrahydropyridines; Tetrahydropyridine;
Wikipedia automatic translation : Pyrrolidine;
MeSH annotation : do not confuse with PYRROLIDONES or PYRROLIDINONES;
Wikipedia link : https://en.wikipedia.org/wiki/Pyrrolidine;
Is substance : O;
Origin ID : D011759;
UMLS CUI : C0034326;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Record concept(s)
Related MeSH Supplementary Concept(s)
- 3,4-APC [MeSH Supplementary Concept]
- 6-propylamino-2,6-propylepimino-2,4,4,8,8-pentakis(pyrrolidin-1-yl)-1,3,5,7,2lambda(5),4lambda(5),6lambda(5),8lambda(5)-teetraazatetraphosphorocine [MeSH Supplementary Concept]
- A 75200 [MeSH Supplementary Concept]
- A 82695 [MeSH Supplementary Concept]
- ABT 200 [MeSH Supplementary Concept]
- ABT 546 [MeSH Supplementary Concept]
- AC 915 [MeSH Supplementary Concept]
- AD 2239 [MeSH Supplementary Concept]
- ARD-61 [MeSH Supplementary Concept]
- ARV-771 [MeSH Supplementary Concept]
- ASP7991 [MeSH Supplementary Concept]
- BD 1008 [MeSH Supplementary Concept]
- BD 737 [MeSH Supplementary Concept]
- BDP 20 [MeSH Supplementary Concept]
- BK 141 [MeSH Supplementary Concept]
- CB-1158 [MeSH Supplementary Concept]
- CMLD-2 [MeSH Supplementary Concept]
- CMP 98 [MeSH Supplementary Concept]
- DA-8010 [MeSH Supplementary Concept]
- DBPR108 [MeSH Supplementary Concept]
- DBPR110 [MeSH Supplementary Concept]
- DX 619 [MeSH Supplementary Concept]
- DuP 747 [MeSH Supplementary Concept]
- E 1487 [MeSH Supplementary Concept]
- E 3800 [MeSH Supplementary Concept]
- E 4101 [MeSH Supplementary Concept]
- EB 1053 [MeSH Supplementary Concept]
- F 1459 [MeSH Supplementary Concept]
- FK 706 [MeSH Supplementary Concept]
- FLA 981 [MeSH Supplementary Concept]
- FLB 457 [MeSH Supplementary Concept]
- FLB 463 [MeSH Supplementary Concept]
- GC376 [MeSH Supplementary Concept]
- GS-680 [MeSH Supplementary Concept]
- GW 3600 [MeSH Supplementary Concept]
- HAPyU [MeSH Supplementary Concept]
- HL156A [MeSH Supplementary Concept]
- IC86518 [MeSH Supplementary Concept]
- IDRX-42 [MeSH Supplementary Concept]
- III-10 [MeSH Supplementary Concept]
- JSM5562 [MeSH Supplementary Concept]
- JSM6427 [MeSH Supplementary Concept]
- KDI 792 [MeSH Supplementary Concept]
- KMN-159 [MeSH Supplementary Concept]
- KRP-109 [MeSH Supplementary Concept]
- LIT-001 [MeSH Supplementary Concept]
- LLY-507 [MeSH Supplementary Concept]
- LNP 906 [MeSH Supplementary Concept]
- LPS 9 [MeSH Supplementary Concept]
- MI-773 [MeSH Supplementary Concept]
- MK-0489 [MeSH Supplementary Concept]
- MK-0616 [MeSH Supplementary Concept]
- MK-8353 [MeSH Supplementary Concept]
- MT-3014 [MeSH Supplementary Concept]
- NK 433 [MeSH Supplementary Concept]
- OBE001 [MeSH Supplementary Concept]
- OP-1074 [MeSH Supplementary Concept]
- PF-543 [MeSH Supplementary Concept]
- QSY-9 [MeSH Supplementary Concept]
- R 84760 [MeSH Supplementary Concept]
- RG7388 [MeSH Supplementary Concept]
- S 16924 [MeSH Supplementary Concept]
- S 34109 [MeSH Supplementary Concept]
- SK-7068 [MeSH Supplementary Concept]
- SP 4012 [MeSH Supplementary Concept]
- SR9009 [MeSH Supplementary Concept]
- SR9011 [MeSH Supplementary Concept]
- TH 1177 [MeSH Supplementary Concept]
- TKB245 [MeSH Supplementary Concept]
- TKS 159 [MeSH Supplementary Concept]
- TRV026 [MeSH Supplementary Concept]
- TRV055 [MeSH Supplementary Concept]
- TRV056 [MeSH Supplementary Concept]
- TSK 159 [MeSH Supplementary Concept]
- TZ6019 [MeSH Supplementary Concept]
- U 69593 [MeSH Supplementary Concept]
- U73343 [MeSH Supplementary Concept]
- UFR2709 [MeSH Supplementary Concept]
- UK-9040 [MeSH Supplementary Concept]
- VH298 [MeSH Supplementary Concept]
- VX-659 [MeSH Supplementary Concept]
- WNK463 [MeSH Supplementary Concept]
- Y 20024 [MeSH Supplementary Concept]
- YL5084 [MeSH Supplementary Concept]
- ZD4054 [MeSH Supplementary Concept]
- hygrine [MeSH Supplementary Concept]
- irniine [MeSH Supplementary Concept]
Semantic type(s)
Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH.
https://www.cadth.ca/fr/fedratinib
2021
false
false
false
Canada
French
drug information
Fedratinib
Inrebic
Product containing only fedratinib in oral dose form (medicinal product form)
pyrrolidines
sulfonamides
---
https://www.has-sante.fr/jcms/p_3258964/fr/givlaari
2021
false
false
false
France
Givosiran
givosiran
acetylgalactosamine
pyrrolidines
insurance, health, reimbursement
adult
porphyria, acute hepatic
injections, subcutaneous
evaluation of the transparency committee
porphyrias, hepatic
porphobilinogen synthase
porphobilinogen synthase
givosiran
---
https://www.has-sante.fr/jcms/p_3280978/fr/maviret-vhc-pediatrique
2021
false
false
false
France
glecaprevir and pibrentasvir
administration, oral
insurance, health, reimbursement
treatment outcome
child
hepatitis C, chronic
antiviral agents
evaluation of the transparency committee
glecaprevir
pibrentasvir
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines
quinoxalines
sulfonamides
---
https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Fedratinib
Fedratinib
drug approval
europe
fedratinib
adult
primary myelofibrosis
Myelofibrosis due to and following polycythemia vera (disorder)
Post-Essential Thrombocythemia Myelofibrosis
orphan drug production
administration, oral
Janus Kinase Inhibitors
Janus Kinase Inhibitors
JAK2 Inhibitor
drug monitoring
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely fedratinib (as fedratinib hydrochloride) 100 milligram/1
each conventional release oral capsule (clinical drug)
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
pyrrolidines
sulfonamides
pyrrolidines
sulfonamides
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form
(medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance
regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines
---
https://www.has-sante.fr/jcms/p_3191915/fr/givlaari
2020
false
false
false
France
Givosiran
Givosiran
acetylgalactosamine
pyrrolidines
givosiran
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
adult
porphyrias, hepatic
acute disease
porphyria, acute hepatic
guidelines for drug use
continuity of patient care
evaluation of the transparency committee
porphobilinogen synthase
porphobilinogen synthase
givosiran
givosiran
---
https://www.has-sante.fr/jcms/p_3191466/fr/lonsurf
2020
false
false
false
France
tipiracil
antimetabolites, antineoplastic
stomach neoplasms
Metastatic gastric cancer
insurance, health, reimbursement
treatment outcome
Gastroesophageal Junction Adenocarcinoma
trifluridine, combinations
evaluation of the transparency committee
trifluridine tipiracil drug combination
trifluridine
drug combinations
drug combinations
pyrrolidines
thymine
---
https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
Givosiran
Givosiran
acetylgalactosamine
pyrrolidines
acute disease
porphyrias, hepatic
drug approval
europe
product surveillance, postmarketing
adult
adolescent
injections, subcutaneous
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
porphyria, acute hepatic
givosiran
porphobilinogen synthase
porphobilinogen synthase
givosiran
givosiran
---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines
---
https://www.has-sante.fr/jcms/p_3224398/fr/maviret
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
glecaprevir and pibrentasvir
Glecaprevir/Pibrentasvir
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
Duration of treatment (qualifier value)
hepatitis C, chronic
glecaprevir
benzimidazoles
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
drug combinations
pyrrolidines
---
https://www.has-sante.fr/jcms/p_3114485/fr/maviret
2019
false
false
false
France
glecaprevir and pibrentasvir
adult
adolescent
hepatitis C, chronic
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
treatment outcome
administration, oral
evaluation of the transparency committee
glecaprevir
quinoxalines
sulfonamides
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines
---
https://www.has-sante.fr/jcms/p_3114479/fr/maviret
2019
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
antiviral agents
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
glecaprevir
pibrentasvir
administration, oral
glecaprevir and pibrentasvir
hepatitis C, chronic
adult
adolescent
renal insufficiency, chronic
Duration of treatment (qualifier value)
glecaprevir
quinoxalines
sulfonamides
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines
---
https://www.has-sante.fr/portail/jcms/c_2848369/fr/relpax
2018
false
false
false
false
France
French
evaluation of the transparency committee
relpax
eletriptan
pyrrolidines
tryptamines
---
https://www.has-sante.fr/portail/jcms/c_2818016/fr/maviret
https://www.has-sante.fr/portail/jcms/c_2818016/fr/maviret-glecaprevir-/pibrentasvir-association-fixe-d-antiviraux-a-action-directe
2017
false
false
false
false
French
treatment outcome
drug combinations
antiviral agents
antiviral agents
administration, oral
hepatitis C, chronic
adult
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
glecaprevir and pibrentasvir
evaluation of the transparency committee
insurance, health, reimbursement
glecaprevir
glecaprevir
benzimidazoles
benzimidazoles
guidelines for drug use
pibrentasvir
pibrentasvir
glecaprevir
glecaprevir
quinoxalines
sulfonamides
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
pyrrolidines
---
Maviret - glecaprevir / pibrentasvir
https://www.ema.europa.eu/medicines/human/EPAR/Maviret
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
treatment outcome
product surveillance, postmarketing
drug combinations
antiviral agents
antiviral agents
tablets
administration, oral
hepatitis C, chronic
adult
drug interactions
pregnancy
breast feeding
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
drug evaluation, preclinical
glecaprevir and pibrentasvir
benzimidazoles
benzimidazoles
glecaprevir
glecaprevir
pibrentasvir
pibrentasvir
glecaprevir
glecaprevir
quinoxalines
sulfonamides
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
pyrrolidines
---
https://www.ema.europa.eu/medicines/human/EPAR/Lonsurf
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
trifluridine
drug combinations
drug approval
europe
treatment outcome
antimetabolites, antineoplastic
antimetabolites, antineoplastic
adult
product surveillance, postmarketing
trifluridine, combinations
colorectal neoplasms
neoplasm metastasis
Metastatic colorectal cancer
administration, oral
aged
drug interactions
pregnancy
breast feeding
contraception
drug evaluation, preclinical
Trifluridine and Tipiracil Hydrochloride
trifluridine tipiracil drug combination
trifluridine tipiracil drug combination
tipiracil
tipiracil
trifluridine
pyrrolidines
thymine
pyrrolidines
thymine
---
http://www.has-sante.fr/portail/jcms/c_2723464/fr/lonsurf
https://www.has-sante.fr/portail/jcms/c_2723464/fr/lonsurf-trifluridine-/-tipiracil-analogue-de-la-pyrimidine
2016
false
false
false
France
French
drug combinations
treatment outcome
antimetabolites, antineoplastic
antimetabolites, antineoplastic
adult
trifluridine, combinations
colorectal neoplasms
neoplasm metastasis
Metastatic colorectal cancer
administration, oral
aged
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
Trifluridine and Tipiracil Hydrochloride
guidelines for drug use
trifluridine tipiracil drug combination
tipiracil
trifluridine
pyrrolidines
thymine
---
eliglustat
https://www.ema.europa.eu/medicines/human/EPAR/Cerdelga
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
eliglustat
eliglustat
eliglustat
drug approval
europe
gaucher disease, type 1
adult
orphan drug production
rare diseases
administration, oral
enzyme inhibitors
enzyme inhibitors
drug monitoring
risk management
product surveillance, postmarketing
drug interactions
breast feeding
pregnancy
ceramide glucosyltransferase
drug evaluation, preclinical
gaucher disease
pyrrolidines
pyrrolidines
glucosyltransferases
---
http://www.has-sante.fr/portail/jcms/c_2023187/fr/brinavess
http://www.has-sante.fr/portail/jcms/c_2023187/fr/brinavess-vernakalant-antiarythmique-de-classe-i-et-iii
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
vernakalant
vernakalant
vernakalant
treatment outcome
atrial fibrillation
adult
anti-arrhythmia agents
anti-arrhythmia agents
infusions, intravenous
anisoles
pyrrolidines
anisoles
pyrrolidines
---
http://www.has-sante.fr/portail/jcms/c_2572136/fr/cerdelga
2015
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
eliglustat tartrate
eliglustat tartrate
eliglustat
gaucher disease, type 1
enzyme inhibitors
enzyme inhibitors
adult
orphan drug production
CYP2D6 gene status assay
cytochrome p-450 cyp2d6
ceramide glucosyltransferase
risk management
gaucher disease
eliglustat
eliglustat
gaucher disease
pyrrolidines
pyrrolidines
glucosyltransferases
---
http://www.cochrane.org/fr/CD009570/buflomedil-dans-le-traitement-de-laccident-vasculaire-cerebral-avc-ischemique-aigu
2015
false
false
false
France
United Kingdom
French
meta-analysis
stroke
brain ischemia
buflomedil
treatment outcome
cardiovascular agents
buflomedil
cardiovascular agents
french abstract
acute disease
buflomedil
buflomedil
pyrrolidines
pyrrolidines
---
http://www.lecrat.eu/?s=Alizapride+-+PLITICAN%C2%AE
2013
France
French
pregnancy
pyrrolidines
antiemetics
alizapride
alizapride
drug information
---
http://www.has-sante.fr/portail/display.jsp?id=c_517698
http://www.has-sante.fr/portail/jcms/c_1554439/fr/relpax
2013
France
French
antimigraine preparations
eletriptan
administration, oral
eletriptan
insurance, health, reimbursement
migraine disorders
receptor, serotonin, 5-ht1b
tablets
receptor, serotonin, 5-ht1d
serotonin 5-HT1 receptor agonists
eletriptan hydrobromide
evaluation of the transparency committee
pyrrolidines
tryptamines
---
https://www.ema.europa.eu/medicines/human/EPAR/Emselex
2012
false
United Kingdom
English
French
syndication feed
Darifenacin 7.5mg m/r tablet (product)
Darifenacin 15mg m/r tablet (product)
drug interactions
benzofurans
benzofurans
pyrrolidines
pyrrolidines
muscarinic antagonists
muscarinic antagonists
treatment outcome
drug evaluation
urinary bladder, overactive
urinary incontinence, urge
urinary incontinence
receptor, muscarinic m3
darifenacin
darifenacin
darifenacin
benzofurans
pyrrolidines
drug evaluation
summary of product characteristics
package leaflet
---
http://www.cochrane.org/fr/CD000988
2009
United Kingdom
France
French
meta-analysis
intermittent claudication
treatment outcome
vasodilator agents
pyrrolidines
buflomedil
french abstract
---
https://minerva-ebp.be/fr/article/369
2008
false
false
minerva-ebm.be
Belgium
French
critical appraisal or critical reading
arteritis
buflomedil
pyrrolidines
vasodilator agents
cardiovascular diseases
---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Enablex-FR.pdf
2006
false
Canada
French
Darifenacin 7.5mg m/r tablet (product)
Darifenacin 15mg m/r tablet (product)
pyrrolidines
urinary bladder, overactive
benzofurans
canada
muscarinic antagonists
darifenacin
darifenacin
benzofurans
pyrrolidines
drug evaluation
---